ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expirat...(pies for vascular disorders. The Company...)

Date:1/25/2008

pies for vascular disorders. The Company's commercialization efforts are currently focused on its product, urokinase for the treatment of acute massive pulmonary embolism. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology.

Cautionary Statement For The Purpose Of The "Safe Harbor" Provisions Of The Private Securities Litigation Reform Act of 1995

Note: Statements made in this press release, which are not historical in nature constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements include those related to our expectation that the FDA approval of our lot release will allow the company to unlock additional value from our unlabeled urokinase inventory and that the company will benefit from cost- savings associated with prolonged shelf-life for future urokinase supplies. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. Such risks and uncertainties include: sales of urokinase may decline and there may be insufficient demand for the product; the FDA may not approve our future requests for lot release which would result in insufficient supply of product thereby reducing sales of urokinase; we may not enter into a final agreement with Microbix for the manufacture of additional supplies of urokinase and the manufacturing process for urokinase may not be successfully transferred to Microbix; and, we may not have or be able to secure sufficient capital to fund our operations and the development and commercialization of our product candidates. All information in this press release is as of January 25, 2008, and the Company undertakes no duty to update this information. A more
'/>"/>

SOURCE ImaRx Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related biology technology :

1. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
2. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
5. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
6. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
7. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
8. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
9. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
10. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
11. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics